The data released by Roche on January 27, 2026, for CT-388 is considered exceptionally strong and positions the drug as a top-tier contender in the "weight loss wars."
The 22.5% weight loss at 48 weeks isn't just a "good" number—it is a "best-in-class" signal that suggests Roche could break the current duopoly held by Eli Lilly (Zepbound) and Novo Nordisk (Wegovy).
1. Comparison vs. Competition
CT-388 is a dual GLP-1/GIP receptor agonist, the same mechanism as Eli Lilly’s Zepbound. However, the Phase II data suggests it may have a slight edge in speed or total efficacy.
| Drug | Mechanism | Avg. Weight Loss | Duration | Context |
| Roche CT-388 | GLP-1 / GIP | 22.5% | 48 Weeks | Phase II (latest data) |
| Lilly Zepbound | GLP-1 / GIP | 20.9% | 72 Weeks | Phase III (SURMOUNT-1) |
| Novo Wegovy | GLP-1 | 14.9% | 68 Weeks | Phase III (STEP-1) |
| Lilly Retatrutide | GLP-1 / GIP / GCG | 24.2% | 48 Weeks | Phase II (the "triple G" bar) |
The Verdict: Roche is outperforming Wegovy significantly and is matching or slightly exceeding Zepbound’s efficacy in a shorter timeframe (48 weeks vs. 72 weeks). It only trails Eli Lilly's "triple agonist" Retatrutide, which remains the highest bar in the industry.
2. Why this data is "Better than Good"
Three specific metrics from the announcement are particularly bullish for Roche:
- No Plateau: Roche noted that the weight loss curve had not reached a plateau at 48 weeks. This implies that if the trial continued to 72 or 80 weeks, the total weight loss could potentially climb toward 25-27%.
- Resolution of Obesity: 54% of patients on the high dose achieved a BMI < 30. Effectively, over half the participants were "no longer obese" by the end of the study.
- Pre-Diabetic Reversal: 73% of pre-diabetic patients returned to normal blood sugar levels. This makes CT-388 a potent "metabolic" drug, not just a weight loss tool, which is critical for insurance coverage.
3. Expectations & Safety
- Expectations: Analysts were looking for anything above 18-20% to consider Roche a serious player. Hitting 22.5% (placebo-adjusted) exceeded the upper end of most "bull case" scenarios.
- Safety Profile: The discontinuation rate (5.9%) is relatively low and "consistent with the class." In these drugs, the main hurdle is whether people can handle the nausea and vomiting (GI issues). Roche’s data suggests their titration (dose-ramping) schedule is working well enough to keep patients on the drug.
4. The "Biased Signaling" Factor
Roche claims CT-388 uses "biased signaling," which is a fancy way of saying the drug stays on the receptor longer without being internalized by the cell. Theoretically, this allows for lower doses to achieve higher results with potentially fewer side effects. The Phase II data validates that this theory is translating into real-world results.
Summary Table: Strategic Outlook
- Speed to Market: Phase III starts Q1 2026. This puts a launch around 2028-2029.
- Market Position: Likely a "Top 3" player alongside Lilly and Novo.
- Commercial Potential: Peak sales estimates are being revised upward, often exceeding $3–4 billion.
Would you like me to compare these results to Roche's other obesity candidate (the oral pill CT-996) to see how their full portfolio looks?